When two-month-old Eliana Nachem developed a lingering cough, her parents assumed it was a minor infection. But as weeks passed and new symptoms appeared, her doctors uncovered something far more serious.
At just four months old, Eliana was diagnosed with severe combined immunodeficiency, or SCID — a rare, life-threatening condition that prevents the immune system from developing.
Living in a Germ-Free World
For Eliana’s parents, the diagnosis meant transforming their Virginia home into a sterile haven. They rehomed their pets, sealed windows, and required visitors to wear gloves, masks, and gowns. Every outside contact posed danger.
SCID, sometimes called “bubble boy disease,” forces families into extreme isolation to protect their children from ordinary germs that could prove deadly.
Searching for Hope
Even as fear set in, Eliana’s parents refused to give up. They learned that her specific form of the disease — ADA-SCID — affects fewer than ten U.S. babies each year.
Traditional treatments offered limited success, but a clinical trial 2,600 miles away in Los Angeles gave them hope. It promised not just survival, but the possibility of a normal life.
The Breakthrough Gene Therapy
In 2014, ten-month-old Eliana joined a groundbreaking trial led by researchers at UCLA. The approach was revolutionary: scientists collected her own bone marrow stem cells, inserted a healthy ADA gene using a harmless, modified HIV virus, and reinfused the cells back into her body. Over time, those cells began to rebuild her immune system from within.
Remarkable Results
The long-term results of the trial, published in the New England Journal of Medicine, were astonishing. Of the 62 children treated between 2012 and 2019, every single one survived.
For 59 of them — including Eliana — the therapy completely restored immune function without the need for additional treatment. It was a 95 percent success rate few dared imagine possible.
A Safer, One-Time Solution
Gene therapy offers a far safer alternative to traditional bone marrow transplants, which rely on donors and carry significant risks. Transplants can trigger graft-versus-host disease, where donor cells attack the patient’s body.
Patients also require strong chemotherapy and lifelong immunosuppressant drugs. Gene therapy eliminates these dangers by using the patient’s own genetically corrected cells.
Fewer Risks, Lasting Benefits
Because gene therapy needs only low-dose chemotherapy, patients face fewer long-term side effects. “There can be growth and fertility issues from traditional treatments,” explained Dr. Whitney Reid of Children’s Hospital of Philadelphia.
The new approach, she noted, minimizes these risks while still rebuilding a functioning immune system. For children like Eliana, that difference is life-changing.
Beyond the Immune System
ADA-SCID does more than weaken immunity. It can lead to developmental delays, hearing loss, and learning difficulties as toxic compounds build up in the body.
By fixing the defective gene directly, researchers not only restore immune defense but may also prevent these complications — giving children the chance to grow, learn, and live without constant medical intervention.
A Model for the Future
Experts say the success of this trial could pave the way for gene therapies targeting other rare conditions. “This is one of the most successful gene therapy trials for an ultra-rare genetic disease that we have,” said Dr. Talal Mousallem of Duke University. “The data is extraordinary — and it’s our hope this becomes the standard of care.”
Life Beyond the Bubble
Today, nearly twelve years after her diagnosis, Eliana is thriving. She takes dance lessons, plays with friends, and enjoys the everyday childhood once out of reach. Her family still monitors her health twice a year, but her immune system remains strong.
“We think it’s a lifelong therapy,” said lead researcher Dr. Donald Kohn. “These kids are growing up — going to prom, living full lives.”
